News & Events zu bioAffinity Technologies Inc (BIAF)BIAFbioAffinity Technologies Inc

bioAffinity Closes Direct Stock Offering at $6.122

bioAffinity Technologies announced that it has closed its previously announced registered direct offering of shares of common stock with an institutional investor at a purchase price of $6.122, in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, the company closed its previously announced concurrent private placement of warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share. The pre-funded warrants have an exercise price of $0.007 per share of common stock, and the warrants have an exercise price of $6.122 per share, will be exercisable following stockholder approval, and will expire five years from the date of stockholder approval. WallachBeth Capital, LLC acted as sole placement agent for the offering. The gross proceeds to the company from the offering were approximately $4M before deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath Lung, its noninvasive test for lung cancer, and general corporate purposes.

bioAffinity Enters Agreement to Sell Shares at $6.122

bioAffinity Technologies announced that it has entered into a definitive agreement with an institutional investor to sell shares of common stock at a purchase price of $6.122 in a registered direct offering priced at-the-market under Nasdaq rules. Additionally in a concurrent private placement the company will sell warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share. The closing of the offering is expected to occur on or about October 9, subject to the satisfaction of customary closing conditions. The gross proceeds to the company from the offering are expected to be approximately $4M before deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath Lung, its noninvasive test for lung cancer, and general corporate purposes. WallachBeth Capital is acting as sole placement agent for the offering.

bioAffinity Technologies Inc Trading Halted Due to Volatility

bioAffinity Technologies Inc trading halted, volatility trading pause